Nuclear Translocation of RhoA Mediates the Mitogen-induced Activation of Phospholipase D Involved in Nuclear Envelope Signal Transduction*

(Received for publication, August 21, 1996, and in revised form, December 4, 1996)

Joseph J. Baldassare Dagger , Matt B. Jarpe §, Lisa Alferes § and Daniel M. Raben §par

From the Dagger  Department of Pharmacology and Physiological Science, St. Louis University School of Medicine, St. Louis, Missouri 63104 and the § Department of Physiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

In this paper we demonstrate for the first time a mitogen-induced activation of a nuclear acting phosphatidylcholine-phospholipase D (PLD) which is mediated, at least in part, by the translocation of RhoA to the nucleus. Addition of alpha -thrombin to quiescent IIC9 cells results in an increase in PLD activity in IIC9 nuclei. This is indicated by an increase in the alpha -thrombin-induced production of nuclear phosphatidylethanol in quiescent cells incubated in the presence of ethanol as well as an increase in PLD activity in isolated nuclei. Consistent with our previous report (Wright, T. M., Willenberger, S., and Raben, D. M. (1992) Biochem. J. 285, 395-400), the presence of ethanol decreases the alpha -thrombin-induced production of phosphatidic acid without affecting the induced increase in nuclear diglyceride, indicating that the increase in nuclear PLD activity is responsible for the effect on phosphatidic acid, but not that on diglyceride. Our data further demonstrate that RhoA mediates the activation of nuclear PLD. RhoA translocates to the nucleus in response to alpha -thrombin. Additionally, PLD activity in nuclei isolated from alpha -thrombin-treated cells is reduced in a concentration-dependent fashion by incubation with RhoGDI and restored by the addition of prenylated RhoA in the presence of guanosine 5'-3-O-(thio)triphosphate. Western blot analysis indicates that this RhoGDI treatment results in the extraction of RhoA from the nuclear envelope. These data support a role for a RhoA-mediated activation of PLD in our recently described hypothesis, which proposes that a signal transduction cascade exists in the nuclear envelope and represents a novel signal transduction cascade that we have termed NEST (<UNL>n</UNL>uclear <UNL>e</UNL>nvelope <UNL>s</UNL>ignal <UNL>t</UNL>ransduction).


INTRODUCTION

It is now clear that a PLD1 is activated as a component of a number of signal transduction cascades (2-7). Cleavage of PC by a PLD results in the production of a free, water-soluble choline head group, and PA. Although in some systems this PA is the source of increased DG levels generated via PA phosphohydrolase, it is now becoming clear that PA itself plays important signaling roles (3, 7-14). There is evidence, for example, implicating the PLD-mediated production of PA as an important component of the mitogenic cascade (3, 9, 10).

We recently advanced the hypothesis that a novel nuclear lipid metabolism is a component of unique nuclear signaling cascades that we defined as <UNL>n</UNL>uclear <UNL>e</UNL>nvelope <UNL>s</UNL>ignal <UNL>t</UNL>ransduction (NEST) (15, 16). The canonical model of lipid-mediated signal transduction assumes that all induced lipid metabolism occurs at the plasma membrane and that the nuclear envelope is a passive participant in the transduction cascade. In the NEST hypothesis, just as the plasma membrane serves as the communication link between the extracellular environment and the cytoplasm, the nuclear envelope mediates the transmission of cytosolic signals to the nucleoplasm. Recently, our laboratory and others have presented compelling data supporting this hypothesis (15-21).

Previous work from our laboratory demonstrated that PC metabolism is a component of NEST (15, 18). One of the PC-hydrolyzing enzymes, PLD, has been identified in the nucleus of Madin-Darby canine kidney cells (19-21), and further studies indicated that this activity may be modulated by RhoA (21). These data suggest that a nuclear PLD is present in these cells, and its activity can be modulated by known signal transduction components.

Clearly, a central tenet of the NEST hypothesis is that the enzymatic activities involved in this cascade are induced in an agonist-dependent manner. Such an agonist-induced nuclear activity has not been demonstrated. The data in this report are the first to demonstrate an agonist-induced increase in a nuclear PLD activity. This activity contributes to the production of nuclear PA but does not affect the level of nuclear DG generated in response to alpha -thrombin. RhoA translocates to the nucleus in response to alpha -thrombin, and removal of this GTP-binding protein with a RhoGDI results in a dose-dependent decrease in nuclear PLD activity. Taken together, the data demonstrate that the addition of alpha -thrombin to quiescent fibroblasts leads to the translocation of RhoA to the nucleus, which mediates the activation of a nuclear PLD.


EXPERIMENTAL PROCEDURES

Materials

Cell culture media were from Life Technologies, Inc. Tissue culture dishes were from Falcon. Bovine serum albumin, highly purified human alpha -thrombin, butylated hydroxytoluene, EGTA, EDTA, quinacrine, 2-nitro-4-carboxyphenyl N,N-diphenylcarbamate, tetraphenylboron, and Trizma base (Tris) were obtained from Sigma. Human transferrin was from Calbiochem. Phospholipase C (Bacillus cereus), aprotinin, and leupeptin were from Boehringer Mannheim. Silica Gel G TLC plates were from Analtech. DG standards were generated by PC-PLC (B. cereus)-mediated hydrolysis of commercial PC, PA, or PE (22, 23), which were purchased from Avanti Polar Lipids. Acetonitrile (high performance liquid chromatography grade) was from J. T. Baker. Isopropyl ether was from Aldrich. Diethyl ether (high purity) and chloroform, methanol, acetone, and hexane (all GC2) were from Burdick and Jackson. All organic solvents contained 50 µg/ml butylated hydroxytoluene. RhoGDI synthesized as a GST fusion protein (plasmid a generous gift from Dr. Gary Bokoch (Scripps Research Institute, La Jolla, CA) in a Escherichia coli expression system was isolated using a glutathione column (24). Palmitoylated RhoA containing a histidine tag (plasmid a generous gift from Dr. Alan Hall, MRC Laboratory of Cellular and Molecular Biology, University College London, London WC1E 6BT, U. K.) was expressed in Sf9 cells and purified using a nickel affinity column (25). GTPgamma S was from Boehringer Mannheim. Anti-RhoA antibodies were purchased from Santa Cruz (SC-179G). Radiolabels were purchased from Amersham Corp.

Cells and Cell Culture

IIC9 cells, a subclone of CHEF18, were grown and serum deprived as described previously (1, 15, 17, 18, 22, 23, 26-29). Briefly, IIC9 cells were grown in 150-mm dishes for 3 days in alpha -MEM/Ham's F-12 containing 5% fetal calf serum. The medium was removed and replaced with serum-free Dulbecco's modified Eagle's medium containing 1 mg/ml grade bovine serum albumin and supplemented with 5 µg/ml human transferrin (serum-free medium). The cells were serum deprived for 2 days and then washed twice in serum-free medium. They were incubated at 37 °C in the fresh serum-free medium for at least 30 min before beginning the experiment. For each experiment, cells were then incubated at 37 °C in serum-free medium either alone or containing 1 NIH unit/ml alpha -thrombin in the presence or absence of ethanol as indicated in the figure legends.

Isolation of IIC9 Nuclei Lipid Analysis

Nuclei were isolated essentially as described previously (15, 18). Briefly, incubations were terminated by removal of medium, transferring the dishes immediately to an ice bath and adding 4 ml of ice-cold fractionation buffer (buffer B: 10 mM Tris, 10 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1 mM phenylmethanesulfonyl fluoride, 10 µM leupeptin, 10 µg/ml aprotinin, 20 µM quinacrine, and 200 µM 2-nitro-4-carboxyphenyl N,N-diphenylcarbamate, pH 7.5 at 4 °C). The cells were scraped from the dishes and subjected to 15 passes in a Potter type Teflon on glass homogenizer. Homogenates from four dishes were used for quantification of DG levels. Homogenation and subsequent steps were carried out at 4 °C.

Nuclei were isolated by centrifugation of the homogenate at 2,000 rpm (700 × g) for 7 min in an RT6000B centrifuge with a swinging bucket rotor. The pellet was dispersed in 5 ml of fractionation buffer and homogenized using a Dounce-type homogenizer with a tight fitting (type B) pestle for 20 passes and layered over a 5-ml cushion of 45% sucrose in fractionation buffer, followed by centrifugation at 2,800 rpm (1,660 × g) for 30 min. The pellet was resuspended in 0.8 ml of buffer B, and a small aliquot was assessed quickly for gross contamination by whole cells and other large debris by light microscopy.

For nuclear lipid analysis, isolated nuclei (typically 50 µg of nuclear protein) were suspended in 0.8 ml of water and transferred into 1 ml of chloroform. The centrifuge tube was washed twice with 1 ml of methanol, and the wash was added to the water and chloroform. Nuclear lipids were extracted (30) and dried under a stream of dry nitrogen.

All other assays, including in vivo assay for PLD, analysis of PA levels, analysis of DG levels, in vitro assay for PLD, treatment of nuclei with RhoGDI, Western blot analysis, were performed as described in the figure legends. Protein was quantified as described by Bradford (33).


RESULTS

alpha -Thrombin-induced Activation of Nuclear PLD

As shown in Fig. 1, PEt in nuclei from cells exposed to alpha -thrombin in the presence of ethanol was approximately a 2-fold higher than it was in nuclei isolated from cells exposed to either alone. These data are consistent with the notion that alpha -thrombin induced the activation of a PLD, which catalyzes the hydrolysis of nuclear PC.


Fig. 1. Effect of alpha -thrombin on nuclear PLD activity in intact cells. Cells were grown, serum starved, and radiolabeled with [3H]myristate as described previously (1). Cells were incubated in fresh serum-free medium in the presence or absence of 1% ethanol for 10 min at 37 °C followed by incubation in the same medium with or without alpha -thrombin (2 NIH units/ml) for 15 min at 37 °C. Nuclei were isolated, and lipids were extracted as described previously (15, 18). PEt was isolated by TLC and quantified by liquid scintillation counting as described previously (1). PEt was normalized to the total amount of radioactivity incorporated into nuclear lipids, and the data are reported as percentage of PEt radioactivity relative to that in control cells (in the absence of thrombin or ethanol, % control), which was 0.46% ± 0.06 = 100%. The total lipid radioactivity was 3.1 ± 0.4 × 105 cpm, 2.4 ± 0.3 × 105 cpm, 2.3 ± 0.2 × 105 cpm, and 2.3 ± 0.3 × 105 cpm for control, thrombin, ethanol, and thrombin plus ethanol, respectively. Data are means ± S.E. from at least six experiments.
[View Larger Version of this Image (98K GIF file)]


The above data demonstrating an activation of PLD acting on the nucleus implies that alpha -thrombin-induced increase in nuclear PA should be blunted in the presence of ethanol. Indeed, alpha -thrombin induced an increase in nuclear PA. Radiolabeled PA as a percentage of total labeled nuclear lipid was 0.233 ± 0.072 in quiescent cells and 0.427 ± 0.034, n = 4, after incubation of cells for 15 min with alpha -thrombin (1 NIH unit/ml). In the presence of 1% ethanol, the increase in PA induced by alpha -thrombin was only 49%, significantly less than the 82% increase induced by alpha -thrombin without ethanol. These data are consistent with the data presented in Fig. 1 demonstrating the activation of a PLD, which acts on the nuclear membrane, and they indicate that this PLD is responsible for most of the PA generated in the nucleus in response to alpha -thrombin.

Nuclear PLD Is Not Involved in the Induced Production of Nuclear DGs

In previous reports, we demonstrated in whole cells that although alpha -thrombin induced the activation of a PLD resulting in the formation of PA, a PC-PLC was responsible for the generation of PC-derived DGs (1). We also demonstrated that alpha -thrombin induced an increase in nuclear DGs in IIC9 cells and that these DGs are derived from PC (1, 15, 17, 18). Because the presence of ethanol inhibited the formation of PA but not DGs even though approximately 50% of the whole-cell DGs induced by alpha -thrombin reside in the nucleus (15), it is unlikely that the nuclear DGs are derived by a PLD/PA-phosphohydrolase pathway.

To test this directly, we evaluated the effect of ethanol on the generation of nuclear DGs in response to alpha -thrombin. As shown in Fig. 2, the presence of ethanol does not significantly affect the production of alpha -thrombin-induced nuclear DGs generated in radiolabeled cells. Similar results have been obtained when the nuclear DG mass is quantified using the DG kinase assay (29 and data not shown). These data demonstrate that the induced nuclear PLD is not involved in the generation of nuclear DGs. In view of previously published data demonstrating that these DGs are derived from PC (15, 18), the present data implicate a PC-PLC in the production of these lipids.


Fig. 2. Effect of ethanol on alpha -thrombin-induced nuclear DGs. Cells were grown, serum starved, radiolabeled with [3H]myristate, incubated with alpha -thrombin and ethanol, and nuclei were isolated as described in the legend to Fig. 1. DGs were isolated by TLC and quantified by liquid scintillation counting (1). DG radioactivity was expressed as percentage of that in total in nuclear lipids, which was 8.7 ± 0.8 × 105 cpm, 10.0 ± 0.9 × 105 cpm, 9.4 ± 0.8 × 105 cpm, and 8.2 ± 0.9 × 105 cpm for control, thrombin, ethanol, and thrombin plus ethanol, respectively. Data are means ± S.E. from at least six experiments.
[View Larger Version of this Image (97K GIF file)]


alpha -Thrombin-modulated Nuclear Acting PLD Is Associated with the Nucleus

In view of the above, it was important to determine if the PLD activated in response to alpha -thrombin was a membrane-associated enzyme. We examined, therefore, the PLD activity in nuclei isolated from quiescent and alpha -thrombin-induced cells. As shown in Fig. 3, PLD activity was increased maximally in the nuclei isolated from alpha -thrombin-stimulated cells after a 15- and 20-min exposure to alpha -thrombin. The data are consistent with the notion that this enzyme is not involved in the production of nuclear DGs as the PLD activity was elevated well after the major increase in nuclear DGs occurred (15, 18). These data demonstrate that a PLD activated in response to alpha -thrombin is associated with the nucleus.


Fig. 3. PLD activity in isolated nuclei. Quiescent cells (open symbols) or cells treated with 1 NIH unit/ml alpha -thrombin (closed symbols) were incubated for the indicated times at 37 °C. Nuclei were isolated as described in under "Experimental Procedures" (15, 18) and resuspended in assay buffer (50 mM HEPES, pH 7.2, 2 mM EDTA, 0.5 mM EGTA, 5 mM dithiothreitol, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 mM orthovanadate) at 4 °C. 400 µl of nuclei (0.14 mg of protein) was incubated with 100 µl of a Triton X-100 (6.25 mM), phosphatidyl[methyl-3H]choline (2.25 mM at 29 µCi/µmol) mixed micelle (3:1, Triton X-100:PC). The reaction mixture (total reaction volume of 500 µl) was incubated at 37 °C for 1 h, and the released water-soluble headgroups were separated by ion paring with tetraphenylboron (31, 32) and quantified by liquid scintillation counting. Data are means ± S.E. from at least three experiments.
[View Larger Version of this Image (16K GIF file)]


alpha -Thrombin Induces the Translocation of RhoA to the Nucleus

There is now strong evidence to suggest that small molecular weight GTP-binding proteins, RhoA in particular, are involved in activating PLD (21). RhoA-mediated PLD activity requires that RhoA be constitutively present in nuclei or translocate to the nucleus in an agonist-induced manner. Western blot analysis of proteins in nuclei isolated from quiescent cells and alpha -thrombin-induced cultures demonstrated that RhoA translocates to the nucleus in response to alpha -thrombin (Fig. 4).


Fig. 4. alpha -Thrombin-induced translocation of RhoA to the nucleus. Growth-arrested IIC9 cells were incubated in serum-free medium with or without alpha -thrombin (1 NIH unit/ml). After 15 min at 37 °C, the nuclei were isolated as described in under "Experimental Procedures." Isolated nuclei were resuspended in sodium dodecyl sulfate-sample buffer and protein (50 µg) separated by electrophoresis in 9% polyacrylamide gels (35) and transferred to Immobilon-P by electroblotting. The blot was incubated overnight in wash buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 0.01% Tween 20) containing 5% dry milk as described (36) followed by washing and incubation for 1 h at room temperature with anti-RhoA antibodies. After washing and incubation for 0.5 h at room temperature with anti-IgG-horseradish peroxidase conjugate, the blot was then developed using chemiluminescence detection (Amersham). Band intensities were quantified by scanning laser densitometry using a Molecular Dynamics laser densitometer (34). The data are representative of at least three experiments. C, cytosol; N, nuclei.
[View Larger Version of this Image (17K GIF file)]


Extraction of RhoA from Nuclei Decreases Induced Nuclear PLD Activity

To investigate further the role of RhoA, nuclei isolated from alpha -thrombin-induced cultures were treated with RhoGDI, and the level of PLD activity was quantified. As shown in Fig. 5, treatment of these nuclei with RhoGDI resulted in a concentration-dependent decrease in nuclear PLD activity. Because this GDI can interact with several members of the Rho family, released protein was examined by Western blot analysis. Only RhoA was found to be released (data not shown). Addition of recombinant, prenylated RhoA, in the presence of GTPgamma S, restored the activity in the RhoGDI-treated membranes (Fig. 6). Interestingly, this RhoA also activates a PLD activity in nuclei isolated from quiescent cells (Fig. 6), suggesting that the enzyme resides in the nucleus. These data provide strong evidence indicating a role for RhoA in the alpha -thrombin-induced activation of a nuclear PLD.


Fig. 5. Effect of RhoGDI on nuclear PLD activity. Nuclei were isolated from IIC9 radiolabeled with [3H]myristate and treated with alpha -thrombin (1 NIH unit/ml at 37 °C for 15 min) as described under "Experimental Procedures." Nuclei (50 µg) were treated with the indicated concentrations of GST-tagged RhoGDI for 30 min at 37 °C. Nuclei were then incubated for 30 min at 37 °C in the presence of 50 µM GTPgamma S and 1% ethanol. [3H]PEt was isolated and quantified as described previously (1). PEt are expressed as the percentage of radioactivity in total nuclear lipids relative to that produced by nuclei not exposed to RhoGDI, which was 0.8% or 7,851 ± 300 cpm (mean ± range).
[View Larger Version of this Image (114K GIF file)]



Fig. 6. Effect of RhoA on PLD activity present in RhoGDI-treated and quiescent nuclei. [3H]Myristate-labeled nuclei were isolated from quiescent and alpha -thrombin-treated cultures (1 NIH unit/ml at 37 °C for 15 min) as described under "Experimental Procedures." 50 µg of nuclear protein of the nuclei isolated from the alpha -thrombin-induced cultures was preincubated with the indicated concentrations of GST-tagged RhoGDI for 30 min at 37 °C. 50 µg of nuclei isolated from alpha -thrombin-treated cultures was treated with GST-RhoGDI (6 µM). These GST-RhoGDI-treated nuclei, as well as 50 µg of nuclei isolated from quiescent cells, were then incubated for 30 min at 37 °C in the presence of 50 µM GTPgamma S and 1% ethanol with or without 5 µM prenylated RhoA. [3H]PEt was isolated and quantified as described in the legend to Fig. 5 (PEt generated in nuclei isolated from the alpha -thrombin-induced cultures was 7,460 ± 70 cpm/50 µg of protein containing approx  9.2 × 105 cpm.) Error bars indicate the S.E. (n = 3).
[View Larger Version of this Image (85K GIF file)]



DISCUSSION

The canonical model of signal transduction cascades involves the initiation of signals at the plasma membrane which stimulate specific cascades leading to the stimulation of activities in target organelles such as the nucleus. For some time it has been assumed that the nuclear envelope played a passive role in these signal transduction cascades. It is becoming increasingly clear, however, that the nuclear envelope is an active participant in signaling cascades, a process we have termed NEST, and that a major component of these cascades is the induction of specific nuclear lipid metabolism (15-21).

In this report we present the first evidence for the involvement of a PC-PLD in NEST and identify one of the components involved in coupling the canonical plasma membrane signaling cascades to this novel pathway in the nuclear envelope. Our data demonstrate that the addition of a potent mitogen, alpha -thrombin, to quiescent IIC9 cells results in increased nuclear PLD activity. This is evidenced by the alpha -thrombin-induced increase in PEt (Fig. 1) and the increased nuclear PLD activity in nuclei isolated from alpha -thrombin-induced cultures (Fig. 3). We further demonstrate that RhoA is at least one of the factors involved in this activation. RhoA translocates to the membrane in response to alpha -thrombin, and treating nuclei isolated from alpha -thrombin-induced cultures with RhoGDI results in a dose-dependent decrease in PLD activity (Figs. 4 and 5). Taken together, these data suggest that the addition of alpha -thrombin to quiescent IIC9 cells induces the translocation of RhoA to the nucleus resulting in the stimulation of nuclear PLD.

Because the GST-tagged RhoGDI used in these studies is too large (approx 50 kDa) to diffuse through a nuclear pore, the above data suggest that the alpha -thrombin-activated nuclear PLD is located on the outer nuclear membrane. In these studies, however, we cannot distinguish between a PLD resident in the outer nuclear membrane which is activated in response to alpha -thrombin and a cytosolic PLD that is translocated to the nucleus during the activation cascade. The activated PLD may translocate to the nucleus, or agonist-induced changes in the nuclear envelope may promote the association of the enzyme with the envelope where it is then activated. Further experiments are in progress to discriminate between these possibilities.

These and other data lend further support to the notion that mitogens activate a PC cycle in the nuclear envelope as a component of NEST. Our data indicate that a PLD is activated by alpha -thrombin, which hydrolyzes PC, resulting in the production of PA in the nuclear envelope. Our data also support the notion that a PC-PLC is involved in the generation of nuclear DGs (15). If a PC cycle were operating in the nucleus, enzymes involved in the biosynthesis would be expected to be present in the nucleus. Indeed, one of the enzymes involved in PC biosynthesis, CTP:phosphocholine cytidylyltransferase, has also been localized in the nucleus (40-42). This enzyme is particularly interesting as it often serves as the regulatory enzyme in PC biosynthesis, and its activity is regulated by diacylglycerol (43, 44). Taken together, these data provide strong support for the hypothesis that mitogens activate a PC cycle in the nuclear envelope as a component of NEST.


FOOTNOTES

*   This work was supported by National Institutes of Health Grant GM51593 (to D. M. R.) and HL40901 (to J. J. B.). The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   Present address: Division of Basic Sciences, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206.
par    To whom correspondence should be addressed: Dept. of Physiology, The Johns Hopkins University School of Medicine, 725 N. Wolfe St., Baltimore, MD 21205-2185. Tel.: 410-955-1289; Fax: 410-276-6685.
1     The abbreviations used are: PLD, phospholipase D; PC, phosphatidylcholine; PA, phosphatidic acid; PE, phosphatidylethanolamine; DG, diglyceride; NEST, nuclear envelope signal transduction; PEt, phosphatidylethanol; GST, glutathione S-transferase; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate.

Acknowledgments

We thank Dr. Carolyn Machamer for helpful discussions and critically reading this manuscript.


REFERENCES

  1. Wright, T. M., Willenberger, S., and Raben, D. M. (1992) Biochem. J. 285, 395-400 [Medline] [Order article via Infotrieve]
  2. Exton, J. H. (1994) Biochim. Biophys. Acta 1212, 26-42 [Medline] [Order article via Infotrieve]
  3. Boarder, M. R. (1994) Trends Pharmacol. Sci. 15, 57-62 [CrossRef][Medline] [Order article via Infotrieve]
  4. Exton, J. H., Taylor, S. J., Blank, J. S., and Bocckino, S. B. (1992) CIBA Found. Symp. 164, 36-42 [Medline] [Order article via Infotrieve]
  5. Exton, J. H., Taylor, S. J., Augert, G., and Bocckino, S. B. (1991) Mol. Cell. Biochem. 104, 81-86 [Medline] [Order article via Infotrieve]
  6. Thompson, N. T., Garland, L. G., and Bonser, R. W. (1993) Adv. Pharmacol. 24, 199-238 [Medline] [Order article via Infotrieve]
  7. Billah, M. M. (1993) Curr. Opin. Immunol. 5, 114-123 [Medline] [Order article via Infotrieve]
  8. Liscovitch, M., Ben-Av, P., Danin, M., Faiman, G., Eldar, H., and Livneh, E. (1993) J. Lipid Mediators 8, 177-182 [Medline] [Order article via Infotrieve]
  9. Inui, H., Kitami, Y., Tani, M., Kondo, T., and Inagami, T. (1994) J. Biol. Chem. 269, 30546-30552 [Abstract/Free Full Text]
  10. Zhang, W., Nakashima, T., Sakai, N., Yamada, H., Okano, Y., and Nozawa, Y. (1992) Neurol. Res. 14, 397-401 [Medline] [Order article via Infotrieve]
  11. Durieux, M. E., and Lynch, K. R. (1993) Trends Pharmacol. Sci. 14, 249-254 [CrossRef][Medline] [Order article via Infotrieve]
  12. Eichholtz, T., Jalink, K., Fahrenfort, I., and Moolenaar, W. H. (1993) Biochem. J. 291, 677-680 [Medline] [Order article via Infotrieve]
  13. van der Bend, R. L., de Widt, J., van Corven, E. J., Moolenaar, W. H., and van Blitterswijk, W. J. (1992) Biochem. J. 285, 235-240 [Medline] [Order article via Infotrieve]
  14. Bocckino, S. B., Wilson, P. B., and Exton, J. H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6210-6213 [Abstract]
  15. Jarpe, M. B., Leach, K. L., and Raben, D. M. (1994) Biochemistry 33, 526-534 [Medline] [Order article via Infotrieve]
  16. Raben, D. M., Jarpe, M. B., and Leach, K. L. (1994) J. Membr. Biol. 142, 1-7 [Medline] [Order article via Infotrieve]
  17. Leach, K. L., and Raben, D. M. (1993) Biochem. Soc. Trans. 21, 879-883 [Medline] [Order article via Infotrieve]
  18. Leach, K. L., Ruff, V. A., Jarpe, M. B., Adams, L. D., Fabbro, D., and Raben, D. M. (1992) J. Biol. Chem. 267, 21816-21822 [Abstract/Free Full Text]
  19. Balboa, M. A., Balsinde, J., Dennis, E. A., and Insel, P. A. (1995) J. Biol. Chem. 270, 11738-11740 [Abstract/Free Full Text]
  20. Huang, C., Wykle, R. L., Daniel, L. W., and Cabot, M. C. (1992) J. Biol. Chem. 267, 16859-16865 [Abstract/Free Full Text]
  21. Balboa, M. A., and Insel, P. A. (1995) J. Biol. Chem. 270, 29843-29847 [Abstract/Free Full Text]
  22. Pessin, M. S., Baldassare, J. J., and Raben, D. M. (1990) J. Biol. Chem. 265, 7959-7966 [Abstract/Free Full Text]
  23. Pessin, M. S., and Raben, D. M. (1989) J. Biol. Chem. 264, 8729-8738 [Abstract/Free Full Text]
  24. Chuang, T. H., Xu, X., Knaus, U. G., Hart, M. J., and Bokoch, G. M. (1993) J. Biol. Chem. 268, 775-778 [Abstract/Free Full Text]
  25. Malcolm, K. C., Ross, A. H., Qiu, R.-G., Symons, M., and Exton, J. H. (1994) J. Biol. Chem. 269, 25951-25954 [Abstract/Free Full Text]
  26. Rangan, L. A., Wright, T. M., and Raben, D. M. (1991) Cell Regul. 2, 311-316 [Medline] [Order article via Infotrieve]
  27. Leach, K. L., Ruff, V. A., Wright, T. M., Pessin, M. S., and Raben, D. M. (1991) J. Biol. Chem. 266, 3215-3221 [Abstract/Free Full Text]
  28. Wright, T. M., Shin, H. S., and Raben, D. M. (1990) Biochem. J. 267, 501-507 [Medline] [Order article via Infotrieve]
  29. Wright, T. M., Rangan, L. A., Shin, H. S., and Raben, D. M. (1988) J. Biol. Chem. 263, 9374-9380 [Abstract/Free Full Text]
  30. Bligh, E. G., and Dyer, W. J. (1959) Can. J. Biochem. 37, 911-917
  31. Kennerly, D. A. (1991) Methods Enzymol. 197, 191-197 [Medline] [Order article via Infotrieve]
  32. Murray, J. J., Dinh, T. T., Truett, A. P., III, and Kennerly, D. A. (1990) Biochem. J. 270, 63-68 [Medline] [Order article via Infotrieve]
  33. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  34. Baldassare, J. J., Henderson, P. A., Burns, D., Loomis, C., and Fisher, G. J. (1992) J. Biol. Chem. 267, 15585-15590 [Abstract/Free Full Text]
  35. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  36. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354 [Abstract]
  37. Deleted in proofDeleted in proof
  38. Deleted in proofDeleted in proof
  39. Deleted in proofDeleted in proof
  40. Wang, Y., MacDonald, J. I. S., and Kent, C. (1995) J. Biol. Chem. 270, 354-360 [Abstract/Free Full Text]
  41. Wang, Y., MacDonald, J. I. S., and Kent, C. (1993) J. Biol. Chem. 268, 5512-5518 [Abstract/Free Full Text]
  42. Wang, Y., Sweitzer, T. D., Weinhold, P. A., and Kent, C. (1993) J. Biol. Chem. 268, 5899-5904 [Abstract/Free Full Text]
  43. Kent, C. (1995) Annu. Rev. Biochem. 64, 315-343 [CrossRef][Medline] [Order article via Infotrieve]
  44. Kolesnick, R. N., and Hemer, M. R. (1990) J. Biol. Chem. 265, 10900-10904 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.